EurekAlert! -
8 Aug 2018 06:00
(University of Colorado Anschutz Medical Campus) CU Cancer Center study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
Share this Article